Skip to main content

Table 1 Baseline characteristics of the 122 one-to-one matched study participants

From: Increased augmentation index in patients with Ehlers-Danlos syndrome

 

EDS cohort (n = 61)

Healthy control cohort (n = 61)

p-value

Sex (f / m)

43 / 18

43 / 18

–

Caucasian, %

100

100

–

Age, years

39.3 ± 14.6

35.6 ± 11.4

0.13

Height, cm

168.5 (161.0/174.5)

169.0 (162.5/176.5)

0.47

Weight, cm

65.0 (54.0/76.0)

65.0 (58.0/75.5)

0.73

BMI, kg/m2

22.7 (20.4/25.9)

22.9 (20.8/24.7)

0.96

BSA, m2

1.3 (1.1/1.5)

1.3 (1.2/1.5)

0.81

Neck, cm

33 (31/37)

33 (32/37)

0.70

Waist, cm

73 (67/85)

76 (69.0/81.0)

0.87

Blood pressure systolic (office), mmHg

117.4 ± 14.2

112.8 ± 12.8

0.07

Blood pressure diastolic (office), mmHg

80.6 ± 10.8

76.1 ± 11.8

0.03

Pulse, min−1

76.7 (67/84.7)

69.0 (64.0/76.7)

0.025

Alcohol units per week, units

0 (0/1)

0 (0/2)

0.74

Current Smoker, n (%)

15 (25%)

9 (15%)

0.20

Diabetes, n (%)

3 (4.9%)

0 (0%)

0.08

Arterial hypertension, n (%)

10 (16%)

1 (2%)

0.004

Pack years of smoking, n

0 (0/3)

0 (0/1)

0.11

Antihypertensive drugs, n (%)

10 (16%)

1 (2%)

0.004

NSAIDs, n (%)

13 (21%)

2 (3%)

0.002

Lipid lowering drugs, n (%)

0

0

–

Antiplatelet drugs, n (%)

1 (1.64%)

0

0.32

Antidiabetic drugs, n (%)

0

0

–

  1. EDS Ehlers-Danlos Syndrome; BMI Body-Mass-Index; BSA body surface area; NSAID non-steroidal anti-inflammatory drugs